Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

2.
3.
4.
5.

Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.

Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.

Value Health. 2015 Sep;18(6):774-82. doi: 10.1016/j.jval.2015.04.008. Epub 2015 Jun 22.

6.

Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.

Plosker GL, Hurst M.

Pharmacoeconomics. 2001;19(11):1111-34. Review.

PMID:
11735678
7.

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.

Thongprasert S, Permsuwan U, Ruengorn C, Charoentum C, Chewaskulyong B.

Asia Pac J Clin Oncol. 2011 Dec;7(4):369-75. doi: 10.1111/j.1743-7563.2011.01463.x.

PMID:
22151987
10.

Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.

Gharaibeh M, McBride A, Bootman JL, Patel H, Abraham I.

J Med Econ. 2017 Apr;20(4):345-352. doi: 10.1080/13696998.2016.1269015. Epub 2016 Dec 21.

PMID:
27919186
11.

Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).

Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA, Evans WK.

Lung Cancer. 2013 Oct;82(1):115-20. doi: 10.1016/j.lungcan.2013.07.012. Epub 2013 Aug 17.

PMID:
23962449
12.

Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer.

Dranitsaris G, Cottrell W, Evans WK.

Curr Opin Oncol. 2002 Jul;14(4):375-83. Review.

PMID:
12130919
13.
14.

Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.

Copley-Merriman C, Corral J, King K, Whiteside R, Voi M, Dorr FA, McDonald RC.

Lung Cancer. 1996 Feb;14(1):45-61.

PMID:
8696720
15.
16.
17.

Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.

Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F, Melotti B, Guaraldi M, Palomba G, Preti P, Petralia A, Artioli F, Picece V, Farris A, Mantovani L.

Eur J Cancer. 2005 Jan;41(1):81-92.

PMID:
15617993
18.

Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.

Wu B, Chen H, Shen J, Ye M.

Clin Ther. 2011 Oct;33(10):1446-55. doi: 10.1016/j.clinthera.2011.09.016. Epub 2011 Oct 11.

PMID:
21992806
19.

Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.

[No authors listed]

Prescrire Int. 2005 Feb;14(75):16-8.

PMID:
15751170
20.

Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.

Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, Dickson R, Ramani VS, Proudlove C.

Health Technol Assess. 2010 Oct;14(Suppl. 2):71-9. doi: 10.3310/hta14suppl2/10. Review.

Supplemental Content

Support Center